Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
Subscribe To Our Newsletter & Stay Updated
